Drug Profile
MRx 109
Alternative Names: MRx-109Latest Information Update: 26 Sep 2023
Price :
$50
*
At a glance
- Originator MyeloRx
- Class Antirheumatics
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Rheumatoid arthritis; Transplant rejection
Highest Development Phases
- Preclinical Rheumatoid arthritis; Transplant rejection
Most Recent Events
- 26 Sep 2023 MRx 109 is still in preclinical trial for Rheumatoid Arthritis in USA (MyelRx pipeline, September 2023)
- 26 Sep 2023 MRx 109 is still in preclinical trial for Transplant rejection in USA (MyelRx pipeline, September 2023)
- 26 Sep 2023 Pharmacodynamics data from a preclinical trial in Rheumatoid arthritis and Transplant rejection released by MyeloRx (MyeloRx pipeline, September 2023)